Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
A new wave of health wearables, called biowearables, provides real-time glucose monitoring through technology that connects directly with the body. Abbott's biowearables, including the newly FDA-cleared Lingo and Libre Rio, offer continuous insights into glucose levels via a smartphone app. This allows users to make informed health decisions in real-time, aiding in energy management, weight loss, and diabetes care. Elite athletes like Eliud Kipchoge have successfully used these devices, highlighting their efficacy. Initially developed for diabetes management with FreeStyle Libre, used by 6 million people globally, biowearables are now accessible to a broader audience for overall health and wellness.
Abbott (NYSE: ABT) announced FDA clearance for two over-the-counter continuous glucose monitoring systems, Lingo™ and Libre Rio™. These systems are based on Abbott's FreeStyle Libre® technology. Lingo is aimed at general consumers wanting to improve their health by tracking glucose levels, offering personalized insights and coaching. Libre Rio is designed for adults with Type 2 diabetes who manage their condition through lifestyle changes, providing a measurement range of 40-400 mg/dL. This move aims to make glucose monitoring more accessible, potentially improving health outcomes and quality of life for a broader population.
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. Tecarfarin has received Orphan Drug Designation from the FDA for preventing thromboembolism in patients with mechanical circulatory support devices like LVADs.
The ARIES-HM3 data indicates a direct correlation between lower therapeutic range times (TTR) and higher bleeding events. The average patient experienced a 30% rate of serious bleeding even without aspirin in the regimen. Incremental improvements in TTR corresponded to significant reductions in bleeding rates, emphasizing the potential of tecarfarin to provide more stable anticoagulation compared to warfarin.
The data is under FDA review, and Cadrenal plans to pursue further pivotal trials to validate tecarfarin's effectiveness for LVAD patients.
Abbott has received FDA approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolving stent for arteries below the knee. This breakthrough technology provides a new treatment option for people with chronic limb-threatening ischemia (CLTI) and peripheral artery disease (PAD). The system offers better outcomes compared to balloon angioplasty, which was the previous standard of care. The LIFE-BTK trial demonstrated that the Esprit BTK System reduces disease progression and improves medical outcomes. This innovation addresses the significant burden of disease and treatment options for patients with severe PAD.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.